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Abstract
Background: Type 2 diabetes (T2DM) patients are at increased risk of cardiovascular
events despite long-term acetylsalicylic acid (ASA) therapy. This study was performed to
establish the prevalence of high platelet reactivity (HPR) on ASA in T2DM and to identify its
predictors.
Methods: The study included 185 T2DM on chronic ASA therapy and to assess platelet
reactivity during long-term ASA therapy, we applied the point-of-care method VerifyNow®
aspirin test (Accumetrics, San Diego, CA, USA).
Results: Compared with the low platelet reactivity (LPR) group, patients with HPR had
higher triglyceride levels (145 vs. 118 mg/dL, p = 0.041), were less frequently treated with
statins (57.1% vs. 75.3%; p = 0.038) and tumor necrosis factor-alpha (TNF-a) concentrations
were higher (2.15 vs. 1.74 pg/mL; p = 0.052). In a multivariate analysis only statin therapy
(OR 0.375; 95% CI 0.15–0.91; p = 0.030) and lower concentrations of TNF-a (for each
1.0 pg/mL: OR 1.3; 95% CI 1.00–1.72; p = 0.046) were predictive of LPR.
Conclusions: Our study provides indirect evidence that the beneficial effect of statins on
platelet activity may be related to their non-lipid-mediated, pleiotropic mechanisms of action.
This might have been partly related to decreased platelet reactivity in patients receiving statin
therapy. In our study in patients with T2DM, platelet reactivity on ASA therapy measured with
VerifyNow® was associated with TNF-a concentrations and statin therapy. These results may
imply a role for subclinical systemic inflammation and a beneficial effect of statins in the
development of HPR in T2DM. (Cardiol J 2012; 19, 5: 494–500)
Key words: acetylsalicylic acid, platelet reactivity, statins, tumor necrosis factor-
-alpha, coronary artery disease
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Introduction
Type 2 diabetes (T2DM) is associated with
progressive atherosclerosis and represents a ma-
jor cause of cardiovascular morbidity and mortality
in developed countries [1]. Despite well-document-
ed benefits, acetylsalicylic acid (ASA) treatment
does not provide complete protection against car-
diovascular (CV) events. Decreased response to an-
tiplatelet agents, defined as an inadequate inhibi-
tion of platelet activation and aggregation when as-
sessed in vitro, constitutes an emerging problem
in CV pharmacotherapy. Thus, in view of the pos-
sible clinical consequences of high platelet reacti-
vity in patients on ASA therapy, a better under-
standing of its etiology and accurate identification
of its risk factors seems of particular importance for
optimizing treatment in patients at high CV risk. In-
creased platelet activity has been also reported in
insulin-resistant patients on ASA therapy. In the
diabetic population, factors related to ASA low-re-
sponsiveness have been reported to include prior
CV disease, obesity, poor glycemic control, insulin
resistance, total, LDL- and HDL-cholesterol con-
centrations, triglyceride concentrations, and mi-
croalbuminuria [2–7]. In order to assess platelet re-
activity in patients with T2DM on long-term ASA
therapy, we applied the point-of-care method ap-
proved by US Food and Drug Administration Veri-
fyNow® aspirin test (Accumetrics, San Diego, CA,
USA) to quantify platelet reactivity. Recent data
showed that VerifyNow® assay measurements dem-
onstrate the lowest day-to-day variation and the
highest repeatability during ASA therapy among
other platelet function tests [8].
The objective of this study was, therefore, to
evaluate the prevalence of high platelet reactivity
(HPR) on ASA therapy in patients with T2DM and
to identify clinical and biochemical variables that
may be predisposed to a decreased response to low-
dose ASA.
Methods
The study consists of preliminary, explorato-
ry analysis of the AVOCADO trial (Aspirin Vs/Or
Clopidogrel in Aspirin-resistant Diabetics inflam-
mation Outcomes Study) results, a multi-center,
prospective, randomized, open-label study. The
study subjects were recruited consecutively from
patients with T2DM presenting to the outpatient
clinic of the Central Teaching Hospital of the Me-
dical University of Warsaw. The local ethics commit-
tee of the Medical University of Warsaw approved
both the study protocol and the informed consent
form. The study was conducted in accordance with
the current version of the Declaration of Helsinki at
the time when the study was designed.
Between January 2007 and October 2008,
642 patients were screened for eligibility. The full
characterization of the study inclusion and exclusion
criteria were published previously [9]. Briefly,
185 patients with T2DM were recruited who, at the
time of enrollment, had been taking ASA tablets at
the dose of 75 mg per day for at least 3 months for
primary or secondary prevention of myocardial in-
farction. No clopidogrel or antiplatelet drugs other
than ASA were used in any of the investigated
patients. All patients had been taking oral antidia-
betic agents and/or insulin for at least 6 months;
diet-controlled diabetic patients were not included.
Compliance to ASA therapy was determined at the
study entry based upon the patient’s own state-
ments and serum thromboxane B2 (S-TxB2) level
measurement.
Blood sample and assay procedures
Blood samples were taken in the morning 2–3 h
after the last ASA dose. Whole blood for S-TxB2
was allowed to clot at 37oC for 1 h before separat-
ing serum by centrifugation. Regular laboratory
testing was performed using standard techniques
and included complete blood cell and platelet
counts, fasting glycemia, glycosylated hemoglobin,
lipid profile, C-reactive protein (CRP) and serum
creatinine concentrations. Serum tumor necrosis
factor-alpha (TNF-a) concentration was quantified
using a commercially available enzyme immunoas-
say: hsTNF-a human (R & D Systems, Abingdon,
UK) according to the manufacturer’s instructions.
Assays were performed in duplicate in batches.
S-TxB2 was measured also with an enzyme immu-
noassay kit according to the manufacturer’s instruc-
tions (Cayman Chemicals, Ann Arbor, MI, USA).
Samples with results outside the standard curve
were re-assayed with appropriate dilutions. An op-
timal compliance was confirmed by S-TxB2 levels
below 7.2 ng/mL in all patients as described previ-
ously in a diabetic population [6, 9]. Of 185 patients
with T2DM, a subgroups of subjects with high plate-
let reactivity (HPR) and low platelet reactivity (LPR)
were selected on the basis of the results of the Ver-
ifyNow® Aspirin Assay system (Accumetrics Inc,
San Diego, CA).
Platelet function analysis
VerifyNow. VerifyNow® Aspirin Assay (Accu-
metrics, San Diego, CA, USA) is a point-of-care
496
Cardiology Journal 2012, Vol. 19, No. 5
www.cardiologyjournal.org
system that uses cartridges containing a lyophilized
preparation of human fibrinogen-coated beads,
arachidonic acid, preservative and buffer. When
aggregation occurs, the system converts luminosi-
ty transmittance units into ASA reaction units
(ARU) for VerifyNow®. According to the manufac-
turer, ARU ≥ 550 indicates no effect of ASA on
platelet aggregation, whereas ARU < 550 indicates
platelet dysfunction due to ASA [8, 9].
Table 1. Important variables impacting on acetyl-
salicylic acid resistance in a simple logistic
regression model.
Variable OR 95% CI P
Gender 1.14 0.54–2.38 0.729
Age [years] 0.82 0.54–1.26 0.374
Total cholesterol 1.54 0.85–1.57 0.359
LDL-cholesterol 1.17 0.92–1.47 0.191
HDL-cholesterol 1.41 0.57–3.50 0.453
Triglycerides 1.13 0.98–1.29 0.093
TNF-a 1.31 1.01–1.70 0.040
hsCRP 0.89 0.71–1.11 0.303
Body mass index 0.86 0.59–1.26 0.446
Waist to hip ratio 0.90 0.60–1.35 0.602
Systolic blood pressure 0.90 0.74–1.10 0.305
Diastolic blood pressure 0.88 0.64–1.20 0.408
Heart rate 0.75 0.51–1.11 0.150
Current smoking 1.20 0.37–3.87 0.760
Fasting glucose 1.05 0.92–1.20 0.440
HbA1c 1.05 0.80–1.41 0.717
Hemoglobin 1.21 0.92–1.60 0.170
Red blood cells 1.13 0.75–1.70 0.563
White blood cells 1.00 0.83–1.21 0.984
Platelet count 0.98 0.72–1.34 0.919
Mean platelet volume 1.02 0.74–1.40 0.923
Fibrinogen 0.89 0.63–1.25 0.495
Serum creatinine 1.02 0.91–1.14 0.702
eGFR 0.83 0.57–1.21 0.328
Statins 0.44 0.20–0.94 0.034
Fibrates 0.79 0.25–2.48 0.689
Metformin 1.53 0.69–3.42 0.298
Sulphonylurea derivatives 0.64 0.30–1.36 0.248
Insulin 1.11 0.51–2.41 0.795
ACE-inhibitors 0.61 0.29–1.29 0.196
Beta-blockers 1.30 0.55–2.94 0.564
Calcium channel blockers 1.73 0.82–3.66 0.148
Nitrates 0.41 0.05–3.33 0.405
Proton pump inhibitors 0.98 0.95–1.11 0.696
OR — odds ratio; CI — confidence interval; LDL — low density lipo-
protein; HDL — high density lipoprotein; TNF-a — tumor necrosis
factor-alpha; hsCRP — high-sensitivity C-reactive protein;
HbA1c — glycosylated hemoglobin; eGFR — estimated glomerular
filtration rate; ACE — angiotensin-converting enzyme
Statistical analysis
Normally distributed continuous variables are
presented as means ± standard deviation (SD),
whereas variables with a highly skewed distribu-
tion are presented as medians (interquartile rang-
es). Categorical variables are presented as frequen-
cies (percentages). Normality of distribution was
assessed using graphical methods. Differences be-
tween HPR and LPR group were analyzed using
Student’s t-test, the Mann-Whitney U-test, the
c2 or Fisher‘s exact test, as appropriate.
Selected variables were checked for associa-
tions with HPR using a univariate logistic regres-
sion model. The final multivariate model was de-
rived using the Akaike information criterion. The
results are presented as odds ratios (OR) with their
95% confidence intervals (CI). All statistical tests
were performed at significance level a = 0.05 (two-
sided). Univariate and multivariate analyses of pre-
dictors for HPR are shown in Tables 1 and 2. The
reported analysis is exploratory and therefore no
formal a priori power analysis was performed.
Results
A total of 185 subjects with T2DM were en-
rolled and their results analyzed. Mean ± SD de-
mographic data, concurrent medications and bio-
chemical and hematological parameters for the
study population are presented in Tables 3–5. In-
adequate platelet inhibition defined as HPR with
75 mg ASA daily was detected in 35 (18.92%) pa-
tients. Patient characteristics were similar among
patients with LPR and HPR patients for all perti-
nent demographic and clinical data (Tables 3–5). Of
the biochemical and hematological parameters eval-
uated, patients with HPR had higher triglyceride
levels (145 vs. 118 mg/dL, p = 0.041) and higher
Table 2. Important variables impacting on high
on acetylsalicylic acid platelet reactivity in
a multiple logistic regression model.
Variable OR 95% CI P
Total cholesterol 0.847* 0.45–1.60 0.608
Statins 1.248** 0.96–1.63 0.103
Triglycerides 1.147† 1.00–1.31 0.046
TNF-a 0.790‡ 0.60–1.04 0.088
hsCRP 0.375 0.15–0.91 0.030
*Odds ratio (OR) for each 50 mg/dL total cholesterol increment;
**OR for each 50 mg/dL triglycerides increment; †OR for each
0.5 pg/mL TNF-a increment; ‡OR for each 2.0 mg/dL hsCRP
increment; CI —  confidence interval; TNF-a — tumor necrosis
factor-alpha; hsCRP — high-sensitivity C-reactive protein
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Table 3. Demographics data.
Characteristics LPR (n = 150) HPR (n = 35) P
Age [years] 66.7 ± 8.5 65.2 ± 9.5 0.375
Female 82 (54.7%) 18 (51.4%) 0.851
Body mass index [kg/m2] 30.7 ± 5.3 29.9 ± 4.6 0.448
Waist to hip ratio 0.97 ± 0.09 0.96 ± 0.09 0.604
Waist circumference [cm] 105.2 ± 13.3 105.4 ± 13.3 0.927
Systolic blood pressure [mm Hg] 143.3 ± 19.6 139.6 ± 17.3 0.306
Diastolic blood pressure [mm Hg] 80.2 ± 11.8 78.3 ± 13.2 0.410
Duration of diabetes [years] 9 (4; 15) 6 (3; 19) 0.607
History of smoking 85 (56.7%) 22 (62.9%) 0.671
Current smoking 15 (10%) 4 (11.8%) 0.757
Dyslipidemia 127 (84.7%) 27 (77.1%) 0.316
Hypertension 134 (89.3%) 32 (91.4%) 1.000
Metabolic syndrome 129 (86%) 30 (85.7%) 1.000
Coronary artery disease 90 (60%) 22 (62.9%) 0.849
Prior myocardial infarction 47 (31.3%) 12 (34.3%) 0.841
Prior stroke 12 (8%) 1 (2.9%) 0.468
Prior TIA 7 (4.7%) 1 (2.9%) 1.000
Heart failure 60 (40.3%) 17 (48.6%) 0.447
LPR — low platelet reactivity; HPR —  high platelet reactivity; TIA — transient ischemic attack
Table 4. Concurrent medications.
Characteristics LPR (n = 150) HPR (n = 35) P
Beta-blockers 104 (69.3%) 26 (74.3%) 0.683
ACE inhibitors 99 (66%) 19 (54.3%) 0.241
Angiotensin receptor blocker 25 (16.7%) 9 (25.7%) 0.229
Aldosterone antagonists 11 (7.3%) 2 (5.7%) 1.000
Loop diuretics 25 (16.7%) 4 (11.4%) 0.607
Thiazide diuretics 50 (33.3%) 13 (37.1%) 0.695
Statins 113 (75.3%) 20 (57.1%) 0.038
Fibrates 21 (14%) 4 (11.4%) 0.791
Calcium channel blockers 49 (32.7%) 16 (45.7%) 0.170
Nitrates 10 (6.7%) 1 (2.9%) 0.693
Proton pump inhibitor 37 (24.6%) 9 (25.7%) 0.897
Metformin 93 (62%) 25 (71.4%) 0.334
Sulphonylurea derivatives 72 (48%) 13 (37.1%) 0.265
Alpha-glucosidase inhibitors 11 (7.3%) 1 (2.9%) 0.468
Insulin 48 (32%) 12 (34.3%) 0.842
LPR — low platelet reactivity; HPR — high platelet reactivity; ACE — angiotensin-converting enzyme
TNF-a concentrations, at marginal significance level
(2.15 vs. 1.74 pg/mL, p = 0.052). HPR group in com-
parison to LPR group had significantly higher level
of S-TxB2 (median 0.16 ng/mL [25; 75 percentiles
— 0.07; 0.47] vs. 1.62 ng/mL [25; 75 percentiles —
0.37; 4.28], p < 0.001). Concomitant medications
were comparable in both groups, with the excep-
tion of statin usage. Patients with adequate plate-
let response to ASA were taking statins more fre-
quently than HPR patients — 113 (75.3%) vs.
20 (57.1%); p = 0.038. No other significant differenc-
es were observed between two investigated groups.
In the simple logistic regression model, only two
parameters were found to be predictive of HPR:
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current statin therapy (p = 0.034) and TNF-a con-
centration (p = 0.040). Variables with p < 0.10 to-
gether with parameters affected by statin therapy
were entered into the multivariate analysis to de-
termine their independent association with ASA
low-responsiveness. Variables associated with HPR
in the multivariate analysis were: TNF-a concentra-
tions (for each 1.0 pg/mL: OR 1.3; 95% CI 1.00–1.72;
p = 0.046; for each 0.5 pg/mL: OR 1.147; 95% CI
1.00–1.31; p = 0.046) and statin therapy (OR 0.375;
95% CI 0.15–0.91; p = 0.030) (Fig. 1). The distri-
bution of TNF-a concentrations in relation to ARU
values is shown in Figure 2. In additional analysis
Table 5. Baseline biochemistry and hematology.
Characteristics LPR (n = 150) HPR (n=35) P
Hemoglobin [g/dL] 13.8 ± 1.2 14.1 ± 1.9 0.296
Hematocrit [%] 41.1 ± 3.3 41.9 ± 5.1 0.435
Leukocytes [103/mm3] 7.0 ± 2.1 7.1 ± 1.6 0.984
Platelet count [103/mm3] 230.9 ± 59.6 229.8 ± 60.5 0.919
Mean platelet volume [fL] 9.8 ± 1.2 9.8 ± 1.2 0.923
Fasting glucose [mg/dL] 127 (110; 151) 133 (113; 156) 0.318
Urea [mg/dL] 42.8 ± 15.1 41.9 ± 16.9 0.756
Creatinine [mg/dL] 1.01 ± 0.32 1.03 ± 0.30 0.703
eGFR [mL/min/1.73] 71.8 ± 21.5 67.9 ± 18.5 0.329
Uric acid [mg/dL] 5.7 ± 1.4 5.7 ± 1.5 0.759
Total cholesterol [mg/dL] 163.7 ± 34.5 169.8 ± 40.2 0.361
Triglycerides [mg/dL] 118 (87; 160) 145 (105; 180) 0.041
HDL-cholesterol [mg/dL] 49.3 ± 14 46.3 ± 14.1 0.259
LDL-cholesterol [mg/dL] 86 ± 29.6 93.6 ± 35.6 0.191
HbA1c [%] 7.1 ± 1.2 7.2 ± 1.2 0.718
VerifyNow [ARU] 452 ± 45 597 ± 39 < 0.001
Serum TxB2 [ng/mL] 0.16 (0.12; 0.47) 1.62 (0.37; 4.28) < 0.001
TNF-a [pg/mL] 1.744 (1.217; 2.423) 2.148 (1.521; 2.696) 0.052
hsCRP [mg/L] 2.8 (1.5; 5.4) 2.3 (1.3; 4.0) 0.405
LPR — low platelet reactivity; HPR — high platelet reactivity; HbA1c — glycosylated hemoglobin; HDL — high density lipoprotein; LDL — low density
lipoprotein; eGFR — estimated glomerular filtration rate; TNF-a — tumor necrosis factor-alpha, hsCRP — high-sensitivity C-reactive protein
0.125 0.25 0.50 1.00 2.00
Odds ratio (95% CI)
Total cholesterol
[50 mg/dL]
Triglicerides
[50 mg/dL]
TNF−
[0.5 pg/mL]
a
hsCRP
[2 mg/L]
Statins
[Yes vs. No]
Figure 1. Results of the multivariate logistic regression
model; TNF-a — tumor necrosis factor-alpha; hsCRP —
high-sensitivity C-reactive protein; CI — confidence in-
terval.
Figure 2. Scatterplot of tumor necrosis factor-alpha
(TNF-a) concentrations vs. ASA reaction units values
by VerifyNow® Aspirin Assay.
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neither the type of statin used, nor the dose of statin
were found to be predictive of HPR in diabetic po-
pulation (OR 1.007; 95% CI 0.280–3.63; p = 0.992).
Discussion
There are relatively few publications, which
focus on identifying risk factors of HPR in patients
with T2DM on ASA therapy. In patients with dia-
betes, the prevalence of residual platelet reactivity
despite ASA therapy has been estimated by others
to be as low as 2.8% up to 22%, which corresponds
to the prevalence of increased platelet reactivity on
ASA therapy observed in this study population
[4, 6, 7, 10]. In comparison to most previous studies,
all of the patients included in our study were tak-
ing an uniform ASA dose of 75 mg as in study pre-
sented by Mortensen et al. [6]. VerifyNow® Aspi-
rin Assay is considered to be an optimal method to
detect ASA effect on platelets as it demonstrates
a very high sensitivity to ASA effect [11]. Thus, it is
not surprising that in our study we observed statis-
tically higher levels of S-TxB2 in the group with HPR
in comparison to the LPR group (Table 5), which is
in accordance to that previously reported [12].
The strengths of the present study are inclu-
sion of a study population of only diabetic patients
with established coronary artery disease (CAD) or
with multiple CAD risk factors and assessment of
compliance. Of the ASA low-responsiveness risk
factors that had been reported previously, only trig-
lyceride concentration differed significantly be-
tween the HPR and LPR groups when investigated
in our study population. However, in the multivari-
ate analysis, triglyceride concentration was not pre-
dictive of HPR. No significant differences between
the HPR and LPR groups were found with respect
to glycemic control or cholesterol concentration.
In the current study, only two variables (i.e.,
TNF-a concentration and statin therapy) were found
to be independent predictors of HPR by the multi-
variate analysis. To our knowledge, this is the first
study to demonstrate a correlation between TNF-a
concentrations and increased platelet reactivity on
ASA therapy in an exclusively diabetic population.
Although the association between inflammation and
enhanced platelet reactivity has long been reco-
gnized, there are only a few reports of increased CRP
and interleukin-6 concentrations in patients with
high platelet reactivity on ASA therapy [13]. Possi-
ble mechanisms linking inflammation with increased
platelet reactivity on antiplatelet therapy include: in-
creased platelet turnover, endothelial dysfunction,
enhanced expression of cyclooxygenase isoenzyme 2,
non-platelet sites of thromboxane A2 synthesis, and
increased levels of various prothrombotic clotting
factors with platelet-activating properties [3, 14].
However, only a few studies that examined the effects
of statins on TNF-a demonstrate that statins either
have no effect on or reduce circulating TNF-a concen-
trations [15–17]. We assume that the ambiguous effect
of statins on TNF-a concentration could in part ex-
plain the observed association with TNF-a, but not
with CRP level. Thus, subclinical systemic inflam-
mation might, therefore, be the key link between
T2DM and high platelet reactivity on ASA therapy.
Our study is also the first one to demonstrate
a possible beneficial influence of statin therapy on
platelet reactivity in a diabetic population on long-
term ASA treatment. To date, only a few studies have
shown a positive effect of statins on platelet respon-
siveness to ASA [18–20]. In the study by Tirnaksiz
et al. [18], high-dose atorvastatin therapy resulted
in improvement of ASA responsiveness in 13 of
20 patients with stable CAD, as assessed with a Plate-
let Function Analyzer (PFA-100®). In another study,
a combination of atorvastatin and ASA in patients
with myocardial infarction reduced thromboxane A2
synthesis and platelet aggregation measured by
light transmission aggregometry (LTA) when com-
pared to patients receiving ASA [18]. In our study,
concomitant statin therapy was predictive of low
platelet reactivity measured with VerifyNow®, ir-
respective of type and dose of statin, or cholesterol
and triglyceride levels.
Our study provides indirect evidence that the
beneficial effect of statins on platelet activity may
be related to their non-lipid-mediated, pleiotropic
mechanisms of action. This might have been partly
related to decreased platelet reactivity in patients
receiving statin therapy.
In our study in patients with T2DM, platelet
reactivity on ASA therapy measured with Verify-
Now® was associated with TNF-a concentrations and
statin therapy. This implies inflammation having
a role in the development of ASA resistance in
T2DM, as well as a protective effect of statins relat-
ed to their lipid-independent mechanisms of action.
Limitations of the study
Our study has two important limitations. First,
we assessed platelet reactivity on ASA therapy with
use of a point-of-care test — VerifyNow® Aspirin
Assay — instead of the “gold standard” LTA [11].
However, the mode of action of the VerifyNow®
Aspirin Assay is similar to LTA, and the VerifyNow®
system is one of the most widely used methods for
assessing platelet function. In addition, according
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to previous reports, the VerifyNow® method de-
monstrates the highest correlation with arachidonic
acid-induced LTA in comparison to other platelet
function tests [11]. Secondly, a prospective, ran-
domized experimental study would be more bene-
ficial for directly demonstrating any beneficial in-
fluence of statin therapy on platelet reactivity. How-
ever, the aim of our current study was to identify
potential independent risk factors of increased
platelet reactivity in a population of T2DM patients
for future investigation. Pretreatment measure-
ments could not be conducted because all patients
included in this study had diagnosed CAD or multi-
ple risk factors for CAD and therefore were on ASA
therapy at the time of enrollment.
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